HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis. A randomized trial.

AbstractSTUDY OBJECTIVE:
To determine the efficacy and safety of adjusted subcutaneous calcium heparin compared with continuous intravenous calcium heparin as the initial treatment for acute deep vein thrombosis.
DESIGN:
Randomized control trial.
SETTING:
University-affiliated general hospital.
PATIENTS:
Of 111 consecutive patients considered, 103 had acute proximal or calf vein thrombosis confirmed by ascending venography and met all other eligibility criteria.
INTERVENTIONS:
PATIENTS were randomly assigned to receive subcutaneous or intravenous heparin. The subcutaneous regimen consisted of an initial dose of 15,000 U, adjusted thereafter to prolong the activated partial thromboplastin time to 50 to 70 seconds. The continuous intravenous regimen was begun as a bolus injection of 5000 U, followed by an infusion of 1250 U/h, adjusted to maintain the activated partial thromboplastin time at 50 to 70 seconds.
MEASUREMENTS AND MAIN RESULTS:
There was no significant difference in the rate of new pulmonary embolism between the two groups, as defined by new high-probability defect on repeat ventilation-perfusion scintigrams of the lung in 96 (93%) of the patients after 7 to 10 days of treatment. Five of forty-seven patients in the subcutaneous group and 5 of 49 in the intravenous group developed pulmonary embolism (95% confidence interval [CI] for the difference, -13.1% to 12.2%). Similarly, there was no significant difference in the frequency of hemorrhagic complications. Five of fifty-one patients in the subcutaneous group and 5 of 52 in the intravenous group had hemorrhagic complications (95% CI for the difference, -11.2% to 11.6%).
CONCLUSION:
Adjusted subcutaneous calcium heparin may be an effective and safe alternative to continuous intravenous calcium heparin in the initial treatment of acute proximal deep vein thrombosis.
AuthorsD J Doyle, A G Turpie, J Hirsh, C Best, D Kinch, M N Levine, M Gent
JournalAnnals of internal medicine (Ann Intern Med) Vol. 107 Issue 4 Pg. 441-5 (Oct 1987) ISSN: 0003-4819 [Print] United States
PMID3307582 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • calcium heparin
  • Heparin
Topics
  • Acute Disease
  • Clinical Trials as Topic
  • Hemorrhage (chemically induced)
  • Heparin (administration & dosage, adverse effects, blood)
  • Humans
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Partial Thromboplastin Time
  • Pulmonary Embolism (diagnostic imaging, prevention & control)
  • Radionuclide Imaging
  • Random Allocation
  • Thrombophlebitis (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: